Article
Oncology
Mustafa Karabicici, Sena Alptekin, Zeynep Firtina Karagonlar, Esra Erdal
Summary: Therapeutic induction of senescence may increase cancer stem cell phenotype, leading to increased tumor aggressiveness and disease recurrence. In liver cancer cells, doxorubicin can induce cellular senescence, increase stem cell gene expression, and cause a shift in stem cell characteristics.
MOLECULAR ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Natalia Izycka, Marcin Rucinski, Malgorzata Andrzejewska, Sebastian Szubert, Ewa Nowak-Markwitz, Karolina Sterzynska
Summary: Recurrent disease and treatment-associated chemoresistance are major contributors to poor clinical outcomes in ovarian cancer patients. This study investigated the expression of CSC-associated markers ALDH1A, CD44, and CD133 to predict patient prognosis. ALDH1A1-positive patients had significantly shorter overall survival (OS) and progression-free survival (PFS). Multivariate analysis revealed that ALDH1A1 expression, FIGO stage III-IV, and residual disease were associated with shorter OS. Targeting ALDH1A1-positive cancer cells may be a promising therapeutic strategy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Jing Li Huang, Masanori Oshi, Itaru Endo, Kazuaki Takabe
Summary: Clinically, patients with high CD24 expression in colorectal cancer tumors have better disease-specific and overall survival rates, and tumors with high CD133, CD24, and CD44 expression are associated with increased EGFR, KRAS, and Ki67 expression. Moreover, CD133-high/CD24-low tumors show potential for predicting worse prognosis in colorectal cancer patients.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Polymer Science
Rakshita Grover, Sahil Drall, Neelam Poonia, Gaurav Kumar Jain, Geeta Aggarwal, Viney Lather, Prashant Kesharwani, Deepti Pandita, Ramesh K. Goyal
Summary: Cancer stem cells (CSCs) contribute to tumor onset, progression, chemotherapy resistance, and relapse. CD44 and CD133 are commonly expressed markers used to identify aggressive CSCs. Targeting these markers with aptamers conjugated nanocarriers can overcome the limitations of antibodies and has proven to be beneficial in targeting CSCs. This article reviews the recent advancements in aptamers and their conjugation with nanocarriers for specific targeting of CSCs and improved cancer therapy efficacy.
EUROPEAN POLYMER JOURNAL
(2023)
Article
Nanoscience & Nanotechnology
Miao Li, Jun Dou, Meng Pan, Hui Xu, Zhiye Xu
Summary: The study demonstrates that miR-7 agomir can inhibit tumor growth in breast cancer stem cells (BCSCs) by reducing CD44 expression, suggesting its potential as a therapeutic agent for breast cancer treatment.
Article
Pharmacology & Pharmacy
Yawei Zhao, Xuehan Yang, Jingtong Zhao, Mohan Gao, Min Zhang, Tongfei Shi, Fan Zhang, Xiao Zheng, Yue Pan, Dan Shao, Jing Li, Kan He, Li Chen
Summary: The study revealed the crucial role of berberine in overcoming chemotherapy-exacerbated ovarian cancer metastasis, by inhibiting the GLI1/BMI1 signaling pathway to reverse EMT and migration, as well as reduce CSC-like characteristics.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Cell Biology
Eriko Nakagomi, Tetuo Mikami, Kimihiko Funahashi, Shinichi Okazumi, Kazutoshi Shibuya, Nobuyuki Hiruta, Yoshinori Igarashi
Summary: This study found that the expression of CSC markers CD133, CD44v9, and ALDH1A1 was higher in both sporadic and UC-associated colorectal tumors. ALDH1A1 expression was higher in the right colon of sporadic cancer and in those with longer disease duration of UC-associated cancer. CD44+/CD133-regions were commonly associated with low apoptosis in both sporadic and UC-associated cancers, indicating them as target areas for CSCs. The combination of CSC markers may differ between sporadic and UC-associated cancers.
HISTOLOGY AND HISTOPATHOLOGY
(2022)
Article
Pathology
Kochli Channappa Niranjan, Monica Raj, Kaveri Hallikeri
Summary: Tumor budding and CD44 expression are of prognostic significance in OSCC.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Biochemistry & Molecular Biology
Masataka Shimonosono, Koji Tanaka, Samuel Flashner, Satoshi Takada, Norihiro Matsuura, Yasuto Tomita, Uma M. Sachdeva, Eishi Noguchi, Veena Sangwan, Lorenzo Ferri, Fatemeh Momen-Heravi, Angela J. Yoon, Andres J. Klein-Szanto, J. Alan Diehl, Hiroshi Nakagawa
Summary: This study demonstrates that ethanol induces oxidative stress in SCC cells, leading to apoptosis of most cells but enrichment of CD44H cells through autophagy. Inhibition of autophagy enhances ethanol-induced apoptosis and reduces CD44H cell enrichment, xenograft tumor growth, and organoid formation. Autophagy may be a potential therapeutic target for ethanol-associated SCC.
Article
Biochemistry & Molecular Biology
Kenly Wuputra, Pi-Jung Hsiao, Wen-Tsan Chang, Po-Hsuan Wu, Lin-Ann Chen, Jian-Wei Huang, Wen-Lung Su, Ya-Han Yang, Deng-Chyang Wu, Kazunari K. Yokoyama, Kung-Kai Kuo
Summary: This study found a close relationship between the overexpression of FOXM1 and regorafenib resistance in liver cancer cells, which were correlated with the survival of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biology
Shenghan Wang, Zhentao Lei, Wei Liu, Jie Xiong, Yuqiang Shi, Lin Yang, Qiang Gao, Kai Le, Bao Zhang
Summary: RCC2, with high expression and low promoter methylation level in PCa, is correlated with regional node metastasis and disease-free survival. Overexpression of RCC2 enhances proliferation, migration, invasion and EMT of PCa cells in vitro, while knockdown suppresses these processes. Further analysis showed involvement of Hedgehog signaling regulator Gli1 in RCC2-mediated PCa progression.
Article
Biochemistry & Molecular Biology
Wang Yin, Cuong Pham, Tao Wang, Hadi Al Shamaileh, Rocky Chowdhury, Shweta Patel, Yong Li, Lingxue Kong, Yingchu Hou, Yimin Zhu, Sunrui Chen, Huo Xu, Lee Jia, Wei Duan, Dongxi Xiang
Summary: This study aimed to overcome drug resistance in liver cancer caused by cancer stem cells by using a CD133 aptamer for targeted delivery of Doxorubicin and enhancing the treatment efficacy through autophagy inhibition. The results showed that CD133 aptamer-guided delivery of Doxorubicin resulted in a higher concentration of Doxorubicin in liver cancer stem cells. The combinatorial treatment strategy of CD133 aptamer-Doxorubicin conjugates and an autophagy inhibitor showed a significantly higher elimination of liver cancer stem cells in vitro.
Review
Medicine, General & Internal
Wael Abdou Hassan, Mohamad Ayham Muqresh, Mohamed Omar
Summary: This study reviewed the literature related to CD44 and CD133 markers in colorectal cancer and discussed their roles in diagnosis, treatment, and prognosis.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Yan S. Kim, Daria M. Potashnikova, Alisa M. Gisina, Irina Kholodenko, Arthur T. Kopylov, Olga Tikhonova, Leonid K. Kurbatov, Aleena A. Saidova, Anna Tvorogova, Roman Kholodenko, Pavel Belousov, Ivan A. Vorobjev, Victor G. Zgoda, Konstantin N. Yarygin, Alexey Yu Lupatov
Summary: CD133 plasma membrane expression is positively correlated with the proliferative activity of cancer cells. Transcriptomic and proteomic profiling revealed minor distinctions between different levels of CD133 expression. The TRIM28 transcription factor plays a prominent role in regulating CD133 expression. Knockout of the TRIM28 gene downregulates CD133 expression in Caco2 cell clones.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Yanguo Liu, Yongming Zhang, Sen Chen, Xinning Zhong, Qing Liu
Summary: The study aimed to investigate the effect of LGR4 with epidermal growth factor receptor (EGFR) in hepatocellular carcinoma (HCC) cells. It was found that overexpression of LGR4 promoted cell proliferation, migration, and invasion, while knockdown of LGR4 or EGFR inhibited these biological activities. In addition, LGR4 overexpression promoted the expression of RSPO2, β-catenin, EGFR, and cancer stem cells (CSCs) markers, while silencing LGR4 or EGFR reduced the expression levels of β-catenin and CSCs markers. Knockdown of LGR4 or EGFR also inhibited tumor growth and reduced the expression levels of RSPO2, CD133, CD44, Nanog, and β-catenin in vivo. The findings suggest that the LGR4/EGFR signaling pathway plays a role in HCC tumor growth and stem cell characteristics, providing a potential target for HCC treatment.